Form 4: Inozyme Pharma COO Disposes All Holdings Following BioMarin Acquisition Completion

Inozyme Pharma's Chief Operating Officer, Matthew Winton, disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by BioMarin Pharmaceutical Inc. for $4.00 per share.

Summary

• Matthew Winton, Chief Operating Officer of Inozyme Pharma, Inc., disposed of all his beneficial ownership in the company's securities.
• This disposition occurred on July 1, 2025, coinciding with the effective time of the merger between Inozyme Pharma, Inc. and Incline Merger Sub, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Under the terms of the merger agreement, each share of Inozyme Pharma common stock was acquired for a cash consideration of $4.00 per share.
• Mr. Winton disposed of 21,743 shares of common stock at the merger consideration price of $4.00 per share.
• All outstanding restricted stock units (41,500 units) were automatically accelerated, fully vested, cancelled, and converted into the right to receive $4.00 cash per underlying share.
• All outstanding stock options (145,000 units) with an exercise price less than the merger consideration ($1.06 per share) were automatically accelerated, fully vested, cancelled, and converted into the right to receive cash equal to the difference between the $4.00 merger consideration and the exercise price.
• Inozyme Pharma, Inc. has now become a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a pre-announced merger, resulting in a cash payout for shareholders and equity holders. This is a definitive positive outcome for those holding Inozyme Pharma shares, as it provides liquidity and a fixed return. The transaction is completed as expected, indicating certainty.

Positives

• The reporting person received a cash payout for all his equity holdings, including accelerated vesting of restricted stock units and stock options.
• Shareholders of Inozyme Pharma received a definitive cash payout of $4.00 per share, providing liquidity and a fixed return.

Negatives

• Inozyme Pharma, Inc. ceased to be an independent publicly traded company.
• The reporting person no longer holds beneficial ownership in Inozyme Pharma, Inc. as a result of the acquisition.

Future Outlook

NA

Industry Context

This transaction represents a common trend of consolidation within the pharmaceutical and biotechnology sectors, where larger companies acquire smaller ones to expand their product pipelines, intellectual property, or market reach. It signifies BioMarin Pharmaceutical Inc.'s strategic move to integrate Inozyme Pharma's assets and capabilities into its portfolio.

Stakeholder Impact

• Shareholders: Received $4.00 cash per share, providing liquidity and a defined return on their investment.
• Employees (specifically Matthew Winton): Equity awards (RSUs and options) were cashed out, providing a financial benefit.
• Company (Inozyme Pharma): Ceased to be an independent public entity, becoming a subsidiary of BioMarin, which will alter its operational and strategic direction.

Next Steps

• Inozyme Pharma, Inc. will operate as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc.
• Inozyme Pharma common stock will no longer be publicly traded on any exchange.

Key Dates

Recommendation

Keywords

Inozyme Pharma, INZY, BioMarin Pharmaceutical, Merger, Acquisition, Form 4, Insider Transaction, Matthew Winton, COO, Restricted Stock Units, Stock Options, Common Stock, Tender Offer, Corporate Action